Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Sichuan Enray Pharmaceutical Sciences Company
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Advaxis, Inc.
Incyte Corporation
Pfizer
Seagen Inc.
Seagen Inc.
Wake Forest University Health Sciences
Eli Lilly and Company
Incyte Corporation
National Institutes of Health Clinical Center (CC)
University of Kansas Medical Center
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Fox Chase Cancer Center
Regenstrief Institute, Inc.
INSYS Therapeutics Inc